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OCCASIONAL REVIEW
Determinants of adherence in adults with cystic fibrosis
L J Kettler, S M Sawyer, H R Winefield, H W Greville
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Cystic fibrosis (CF) is now as much a disease of adults
as of children and adolescents. An important focus of
recent research has been the impact of the complex,
expensive, and time consuming routine of self-care and
medical treatment that is required by adults with CF to
maintain health. A growing concern for medical and
allied health teams is the issue of patient adherence to
prescribed health management plans. A summary of the
particular medical and treatment context of CF is
followed by a review of adherence measurement issues
and the determinants of adherence to treatment
regimens in people with CF, primarily adults. Evidence
for factors which influence adherence decisions of
people with CF is examined. The medical and
psychological aspects of this complex problem have not
been adequately addressed because of difficulties with
definition and measurement. Only a small proportion of
the variance in adherence has been accounted for in
the literature. New measurement technologies and new
theoretical directions offer promise for a better
understanding of this complex and important issue and
may result in more effective intervention strategies to
improve adherence.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
DEMOGRAPHIC DATA, AETIOLOGY, AND
TREATMENT OF CYSTIC FIBROSIS
Cystic fibrosis (CF) is the most common severe
genetically inherited condition in the population
of north west European descent, affecting ap-
proximately one in every 2500 live births.1
Significant advances in the management of respi-
ratory infection and pancreatic insufficiency, cou-
pled with better quality of care by specialist
multidisciplinary teams, have resulted in a
significant improvement in life expectancy to
around 30 years.2 Preventative management and
symptomatic treatment is instituted in early
childhood for most people with CF, so manage-
ment and treatment routines have been a daily
concern for most adults with CF for many years.
People with CF have relatively good psycho-
social health.3 The incidence of recognisable men-
tal health disorders in people with CF is very
similar to that in the general population.4
However, high levels of stress and, intermittently,
high levels of distress are common and require
recognition and attention. Moise et al5 noted
higher self-esteem, lower levels of psychological
distress, and better adaptation in patients who
used avoidant coping strategies than in those who
used more direct and positive coping methods.
More recently, Abbott et al6 found that adults with
the most serious disease more often reported
their health to be better than others with CF. As
will be discussed later, these findings raise
questions about the interactions between treat-
ment adherence and the use of coping strategies
which depend on a high level of denial of the dis-
ease process and its threats to ongoing health and
physical wellbeing.
Better life expectancy has brought with it the
challenges of maintaining a complex and time
consuming CF treatment regimen.7 For most
people with CF,management involves continuous
home care with daily prophylactic medications
such as oral or nebulised antibiotics, pancreatic
enzymes, nebulised mucolytic agents, and vita-
min supplements, as well as daily physiotherapy
treatments.8 Ideal home care also involves opti-
mising nutrition and exercise. From time to time
most patients with CF require admission to
hospital for intravenous antibiotics and intensive
physiotherapy treatment of acute infective exac-
erbations of their lung disease.8 CF can also be
complicated by diabetes9 and liver disease, condi-
tions requiring substantial day to day manage-
ment routines in their own right. There is also a
growing concern about bone disease associated
with CF.10 Lung transplantation does not reduce
the requirement for ongoing self-care and close
supervision.
In view of the complexity and extent of the
treatment requirements for CF, ongoing adher-
ence to treatments is of interest and concern to
CF clinicians.
ADHERENCE TO MEDICAL REGIMENS
Poor adherence to medical advice and treatment
in chronic illness in general is well documented,
with reports of patient adherence rarely exceed-
ing 80% and more often falling between 30% and
70%.11 The extent to which people adhere to
recommended treatments appears to depend on
the complexity and longevity of both the disease
and its treatment. Research results are also influ-
enced by the particular definition of adherent
behaviour and the measurement strategies
employed.12 In a substantial review of studies on
life threatening disorders,13 the mean adherence
rate for long term preventative regimens was
found to be only 57% while the mean adherence
rate for long term treatments was slightly less at
54%.
The consequences of poor adherence—both for
individuals and in terms of costs to the health
system—are significant.14 Cluss and Epstein12
cited “exacerbation of disability, progression of
the disease, more frequent medical emergencies,
unnecessary prescriptions of more potent and/or
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toxic drugs and, ultimately, failure of treatment” to be impor-
tant consequences of poor adherence to medical regimens and
treatments.
Other reasons for examining patient adherence include
quality assurance and accuracy in clinical trials11 and the col-
lection of accurate data on the efficacy of ongoing treatments.
The study of adherence may also allow us to gain a better
understanding of patients’ health beliefs and behaviour that
hopefully will be a precursor to the design of better treatment
programmes and improved relationships between patients
and health professionals. This latter goal takes on particular
significance in light of the dilemma which exists for health
professionals between promoting good psychological health
(and perhaps condoning and accepting denial and avoidance
coping strategies) and promoting adherence, which is
dependent on attention to and recognition of the disease
process and the need to treat it.
Definition of adherence
The terms “compliance” and “adherence” are generally used
interchangeably in the literature. However,Meichenbaum and
Turk11 argue that there is an important difference between
them. They define compliance as “the extent to which patients
are obedient and follow the instructions, proscriptions, and
prescriptions of health care professionals”, while adherence is
defined as an “active, voluntary, collaborative involvement of
the patient in a mutually acceptable course of behaviour to
produce a desired preventative or therapeutic result”. Al-
though this is a useful definition and helps to conceptualise
adherence, it does not assist in the establishment of criteria to
define adherence behaviours—it does not tell us what
someone must do to be considered adherent to a particular
therapeutic or preventative regimen.
Many studies have found that substantially less than 100%
adherence is sufficient to result in desired health changes.
Gordis15 suggested that a suitable criterion for adherence
behaviours is “the point below which the desired preventative
or desired therapeutic result is unlikely to be achieved”.
Meichenbaum and Turk advocated the need to develop specific
criteria based on particular conditions and treatments, rather
than adopting general criteria for adherence behaviours.
While this appears to be an acceptable criterion, it is only
practical for those conditions where it is known how much of
any prescribed behaviour is required to produce the desired
effect.11 The chronic and variable nature of CF with its
interdependent components of care and lack of knowledge of
“how much is enough” for most aspects of the CF health care
regimen make determination of such criteria an ongoing
process of adjustment and balance.
Lask16 suggested that patients should be described as fully
adherent, partially adherent, or non-adherent—that is, he dif-
ferentiated patient adherence using a quantitative approach.
He noted that people may be adherent to some components of
treatment and not others, and cautioned against the global
labelling of patients as adherent or non-adherent. Koocher et
al17 suggested that there are three different types of
non-adherence: those who have inadequate knowledge, those
who present psychosocial resistance, and those who are
educatedly non-adherent—that is, have made an informed
choice not to adhere. Lask16 classified non-adherent patients
on the basis of their behaviour into three groups: “refusers”
who say they don’t want or don’t need a particular treatment;
“procrastinators” who are likely to say they will adhere more
in future but never seem to get around to it; and “deniers”who
will not admit to any non-adherence even when it is quite
clear that their adherence is poor. Unfortunately, despite the
recognition of various degrees and types of adherence,most of
the literature reports adherence as a dichotomous construct—
either adherent or non-adherent. We hypothesise that the
majority of clinicians hold a similar view.
What emerges from these considerations is the importance
of developing reasonable criteria for adherence which suit the
specific context of patients’ behaviour.
Measurement of adherence
The measurement of adherence is problematic. The most com-
monly reported techniques are to ask the patient, ask the phy-
sician, ask patients to keep a diary of their actions, count
remaining pills, count the number of filled prescriptions, and
review themedical record. All of these are indirect measures of
the target behaviour and all are subject to problems of report-
ing bias, reporting errors, or intentional manipulation on the
part of the reporter. Compared with more direct measurement
techniques, all of the techniques described above have been
shown to overestimate adherence.12 18
Another common approach involves drawing retrospective
conclusions about adherence based on the therapeutic
response, although this method carries substantial assump-
tions about the predictability and reliability of treatment
responses to particular medications or other forms of
treatment.18 When considering a complex disease such as CF,
this method also forces assumptions about the interactions
between different treatment elements and the stability of
treatment effects for treatments other than the one targeted—
for example, interactions between antibiotics and physio-
therapy in the treatment of respiratory infections.
More direct measurement techniques have also been
employed. In particular, blood serum levels or urinary
excretion of medications, their metabolites, or of a tracer sub-
stance have been used to measure adherence with varying
degrees of success. These methods have their own limitations,
particularly the issue of pharmacokinetic variation.19 An addi-
tional concern with laboratory based measurements of adher-
ence is the cost in time,money, and acceptability to the patient
of collecting and analysing the data. Many blood and urine
assays are only able to provide an accurate measure of the
amount of medication consumed in the preceding 24 hours20
so, while such a measure may provide information about the
patient’s adherence on the day before the test, daily testing
would be needed to make an accurate assessment of
adherence. Clearly, this kind of approach is invasive, expen-
sive, and impractical for longer term treatment regimens.
There are a smaller number of reports of other more direct
attempts to measure adherence behaviours using various
electronic recording devices attached to pill bottles, aerosol
dispensers (puffers), and nebulisers which record the date and
time of each use of the dispenser.21–25 These data can be
periodically downloaded for analysis and provide a more
dynamic and longitudinal view of adherence than was previ-
ously possible. Researchers in this area report high levels of
accuracy and reliability with these devices.22–25 The method-
ology offers advantages over both direct biological methods
and diary reporting methods:
• The recording devices are non-invasive, relatively non-
intrusive, and less dependent on patient cooperation for the
collection of data.
• They allow for the continuous collection of data over a long
period of time without the patient having to attend the
clinic.
• They provide a measure of behaviour—not of belief,
memory, or drug effect.
The main downside of these devices is their high unit cost
price. They are, however, inexpensive to maintain and are
usually reusable over a considerable period of time.
This type of monitoring has its own limitations. The data
provide information about the use of a medication dispenser,
not about whether the patient actually ingested the medi-
cation removed from the dispenser. However, it is reasonable
to assume that most patients who make the effort to remove
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medication from the dispenser in the prescribed way (particu-
larly over a long period of time) will also consume the medi-
cation. This technology is presently limited to medications and
certain other specific activities (such as physiotherapy using a
physiotherapy vest) and cannot provide us with information
about adherence to treatment regimens such as exercise or
diet. Researchers using these devices have also questioned
whether this form of monitoring actually changes adherence
behaviour—that is, whether the knowledge that their
medication is being monitored causes patients to adhere bet-
ter to the medication. This is an interesting question which
holds both surprises and possibilities. It has been shown that,
even when the monitoring has been explained to the patient,
adherence behaviour is not significantly affected by monitor-
ing alone21 24 and that, where monitoring does change
adherence, the effect is very short lived.18 23 Rand et al23 found
that this form of monitoring allowed them to identify
instances of medication “dumping” (the repeated use of the
medication dispenser, far beyond prescribed levels, shortly
before medical appointments) which could not be detected
from other adherence measures, a finding that is inconsistent
with the idea that monitoring itself improves long term
adherence behaviour.
These findings may appear to be in contrast to the large
body of psychological literature on the effectiveness of
self-monitoring techniques in effecting behavioural change.26
Self-monitoring requires the patient to monitor and keep a
written record of instances of a particular behaviour or
emotion as part of a treatment programme, an approach used
with many mental health disorders. It is known from this field
of work that self-monitoring alone is usually insufficient to
bring about desired changes in behaviour. The technique
becomes effective with the addition of goal directed modifica-
tions of cognition and behaviour based on the self-monitoring
observations. Of particular interest for the future are the
opportunities presented by the merger of medication and
health monitoring technologies and the methodology of self-
monitoring to assist behavioural change—for example, the
use of blood glucose monitors by people with diabetes in
assisting dietary management and diabetic control.27 28
PREDICTORS OF ADHERENCE IN ADULTS WITH CF
People with CF often receive little positive reinforcement for
their efforts to adhere to treatment. Furthermore, CF is an
inexorable disease and, even with complete adherence, the
health of an adult with CF will eventually decline. At best,
good adherence is thought to reduce the rate of decline of res-
piratory disease. There is the real risk that adherence may be
worse in those with the most severe disease because of the
lack of positive reinforcement from any beneficial effect of
treatment adherence.29
The treatment demands placed upon adults with CF are
extraordinary when compared with most other chronic
illnesses, let alone when compared with the healthy popula-
tion. In addition to the complexity and number of treatments
prescribed for adults with CF, adults living with this condition
are faced with the challenge of interpreting and understand-
ing the effects and priority of each of these treatments within
their own treatment regime. It is not surprising that patients
find this difficult, given the lack of consensus among treating
physicians and multidisciplinary health care teams about
which treatments are most important.7 30
People with CF often develop strong relationships with their
multidisciplinary health teams. These relationships are
usually developed over many years of treatment; CF is one of
only a handful of chronic illnesses in which such long term
treatment relationships may be developed. This feature of
health care in CF will impact (both positively and negatively)
on the communication between the health care professional
and the patient.30 Such a relationship may enhance the clarity
of the communication and may lend an important source of
support to the patient. Importantly, though, it may also lead to
assumptions on the part of both the health care professional
and the patient about shared knowledge of the concerns to be
dealt with and the treatment programme overall. The
physician, physiotherapist, or dietician may assume, for
example, that a patient knows how to manage a particular
aspect of treatment if the subject has been discussed in a pre-
vious consultation. This assumption may be fair for much of
the time, but there will be occasions when important
information has not been exchanged which may result in
adherence difficulties being unrecognised by both the CF team
and the patient.
The disruption to longstanding health care relationships
when older adolescents transfer their care from a paediatric to
an adult facility must also be considered.31 The process of
transfer can be an unsettling experience for some while, at the
same time, it may herald a new sense of belonging or a fresh
start. Important changes of this kind can impact on the
dynamics of patients’ self-perceptions and perceptions of
place and belonging.32 In particular, transfer to an adult unit
can signal a different level of parental involvement and super-
vision of the health care regimen for some young people.
Changes in the dynamics of adherence may be predicted as
part of this overall change process.
At present there is no information about the relationship
between family functioning and either health outcomes or
adherence in adults with CF. Unlike their healthy peers, more
adults with CF remain within the family home or live alone
than marry or share accommodation with others.3 It could be
predicted that family functioning may be an important medi-
ating variable for adherence for those adults who continue to
live with immediate family and those who marry, but less so
for adults with CF living independently. In this group, a
broader definition of what constitutes family may be
important to consider. The role of family cohesion, conflict,
and stress have been linked to longer term trends in
pulmonary functioning and weight gain for children and ado-
lescents with CF.33–35 While the mechanisms for these links
remain unclear,7 it has been postulated that treatment adher-
ence is the mediator of the effect, with those patients experi-
encing lower family stress, higher parental availability, and
positive family coping adhering better to treatments and
enjoying better health.
A limited number of studies have reported on adherence in
adults with CF. Most are of an exploratory nature and employ
self-reports, physician reports, or medical record reviews as
their measurement strategy. As noted, these measurement
strategies are problematic, raising concerns about the validity
of the information which is likely to overestimate the extent of
true adherence.
These early self-report and physician report studies indicate
that the level of adherence to antibiotic treatments (oral or
intravenous) is relatively high (80–95%).36 This is a consider-
ably higher rate of adherence to a longer term treatment than
the figures previously found across a wide range of illnesses.13
Adherence to nebulised medications and pancreatic enzymes
is reported to be moderate (65–80%) which is also better than
the figures reported more generally for long term regimens.
However, adherence to vitamin therapy, dietary changes, exer-
cise, and physiotherapy is generally reported to be poor (40–
55%).37
These findings are consistent with the literature on adher-
ence generally which suggests that adherence decreases as the
duration and complexity of treatment increases.30 Interest-
ingly, disease severity and general knowledge about CF are
poorly associated with adherence,37 38 while worry about the
condition and trust in medical practitioners appear to be
related to greater levels of adherence.39 When asked specifi-
cally about why they do not adhere to treatments, adults with
CF most often cite forgetfulness.36 37
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There are significant limitations in the literature on adher-
ence in adult patients with CF. In addition to the problems
with measurement techniques, studies to date have been cross
sectional in design and have presented a static picture of
adherence. There has been no literature examining variability
in adherence over time. Most studies report treatment factors
(such as complexity and time) or trait factors (such as worry
and confidence) as explanations for poor adherence. While
these factors appear to have some explanatory value, most of
the statistical effects are small, leaving significant amounts of
the variance in adherence behaviour unaccounted for.
MODELS OR THEORIES APPLIED TO ADHERENCE IN
CF
Theories previously applied
Efforts to understand adherence behaviour in CF through the
application of theoretical models have met with limited
success. The health belief model,40 the health locus of control
construct,41 and various models of coping42 have been applied.
In addition, consideration has been given to the social cogni-
tive theory of Bandura43 and, in particular, the concept of self-
efficacy (the confidence to perform a particular behaviour).
Abbott et al39 found little support for the health belief model
as a predictor of adherence in adults with CF. They were
unable to discriminate between adherent and non-adherent
patients on the basis of their health beliefs, with the exception
of finding that those patients who worried more about their
illness reported better adherence to most of their treatments.
The results with the health locus of control model were more
encouraging. Patients who believed that “chance factors” or
“powerful others” controlled their health reported better
adherence to physiotherapy regimens, enzymes and vitamin
supplements, while those who believed they were in control of
their own health reported better adherence to exercise
regimens.
These findings warrant further investigation. Self-report of
adherence behaviour was used in this study as the basis of
testing the two theoretical models. However, it is likely that
only a study using more objective measures of adherence will
clarify the contribution of these theoretical models to the issue
of adherence. It certainly seems reasonable to predict that
patients who perceive their illness as serious, believe that
treatment is beneficial, and are motivated or concerned for
their health (as described in the health belief model) would
adhere better to prescribed treatment programmes.
Czajkowski and Koocher42 explored the predictive value of
six coping behaviours (understanding the severity of the
illness, taking responsibility for medications at home, seeking
information about the illness, future goal orientation, involve-
ment in school or work, and openness with peers about
illness) in distinguishing between adherent and non-adherent
adolescents with CF. Reports of whether or not they used
these coping behaviours reportedly discriminated between
adherent and non-adherent patients; those who used the cop-
ing behaviours also had better adherence.
Parcel et al44 evaluated the importance of various skills in
maintaining adherence to the CF treatment programme. Skills
included confidence in managing various aspects of medical
treatment, symptom and behaviour monitoring, communica-
tion, and adjustment. They found that self-efficacy was the
most important factor in predicting whether patients and
their caregivers effectively monitored health and treated
respiratory problems.
New theoretical directions
Previous studies13 suggest that the difficulties experienced by
patients in achieving adherence are not disease specific, so it is
appropriate to investigate models which have been applied to
other diseases and in other disciplines in adults with CF. New
models in health psychology offer unexplored possibilities for
understanding the mechanisms which influence adherence to
treatment in adults with CF. In particular, the self-regulatory
model45 has led to developments in the understanding and
measurement of health behaviours including adherence to
treatment. This model suggests that health related behaviours
(including adherence) are influenced by the beliefs or
cognitive schema (labelled “illness representations”) which
the patient holds about the illness. In this model it is consid-
ered that people structure their beliefs around the following
five separate components or themes relating to the illness:
“identity”, “time line”, “cause”, “consequences”, and “cure/
control”.
A questionnaire measure was developed by Weinman et al46
to measure patients’ perceptions of their illness across these
themes. Responses on this measure predicted patients’
attendance for rehabilitation and their return to work follow-
ing a myocardial infarction,47 suggesting a link between illness
perceptions and adherence behaviours. The measurement of
illness representations in adults with CF may assist us to pre-
dict the way in which they will adhere to their treatment and
therefore to plan ways of managing the effects of illness rep-
resentations on adherence.
Horne48 examined beliefs about medicines using the
concept of illness representations but targeting the treatment
rather than the illness itself. It has been found that the beliefs
that patients hold about the necessity of medications
prescribed for them as well as specific concerns about poten-
tially adverse effects of their medications account for a signifi-
cant amount of the variance (15–20%) in reported adherence
to those medications. Across more than seven illness groups it
was found that patients with a stronger belief about the
necessity of their medication were more adherent than those
with stronger concerns about potentially adverse effects.
Patients who reported both a strong belief in the necessity of
their medication as well as reporting a high level of concern
about adverse effects were less adherent. It was hypothesised
that such patients perform a “cost/ benefit analysis” of the
pros and cons of taking medication, trying to minimise the
perceived risks of the medication by taking less than the pre-
scribed dose.
We propose that specific knowledge about a prescribed
treatment may also influence the cost/benefit analyses
performed by patients. It has been found that, although
knowledge about CF in general has a very limited relationship
with treatment adherence, there are strong relationships
between accurate knowledge of a specific treatment regimen
and better adherence to the regimen, at least among
adolescents with CF.49 50
It seems therefore that the combination of better measure-
ment techniques and appropriate theoretical models to guide
our research questions may help us to predict (and test) more
accurately the way in which people with CF adhere to their
treatments.
DIRECTIONS FOR FUTURE RESEARCH
Adherence behaviour in patients with CF (particularly adults)
is currently poorly understood and has been researched using
exploratory and somewhat crude methodologies. We have not
begun to understand the dynamics of symptom and treatment
interactions which may guide the beliefs and decisions of
adults with CF about how to adhere to their many and
complex treatments, nor do we understand the processes and
patterns which may be involved in treatment relationships
between health professionals and patients over time.We know
that many young people find it disruptive and unsettling to
move from paediatric to adult services. We understand that
people adhere with less consistency to more complex and time
consuming treatments and we suspect that people who worry
more about their disease adhere better to their treatments
than those who are less worried. We have no information,
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however, about the way patients perform their treatments over
time, and no accurate or objective information about how
adherence to different treatment components relates to health
outcomes in CF. People with CF are living longer, but we know
that there is a high cost in both treatment demands and the
development of additional symptoms in many cases.
If we are to develop our understanding of and ability to pre-
dict adherence to treatments in patients with CF (with the end
goal of improving adherence), longitudinal studies of adher-
ence behaviours are indicated with effective measurement
tools. This is necessary as the current literature does not allow
any understanding of the changing nature of adherence over
time, with increasing age and maturity or disease severity. The
complexity of the CF treatment regimen also provides an
important opportunity to study adherence behaviour concur-
rently within multiple different management regimens (e.g.
physiotherapy, antibiotics and vitamins). These studies are
necessary if we are to gain an understanding of the
relationship between adherence and outcome in CF.
There are additional research challenges in relation to
adherence which face the CF community. The issue of
adequate criteria for adherence, both from a clinical and a
research point of view, remains unresolved. International—
and, in many cases, national—agreement about minimal
standards of care in CF is yet to be achieved, together with an
understanding within different treatment regimens of how
much is enough. These issues make discussion about
adherence criteria fraught with uncertainty. We have a poor
understanding of the different adherence challenges faced by
patients with CF who have different levels of disease severity
and who are at different life stages. What may be true for one
patient at a particular stage of life may not be true or
appropriate for another at a different developmental stage. It
is likely that qualitative studies will provide a deeper
understanding of these issues.
On a broader level, CF and other chronic illnesses pose a
challenge for those training doctors and other health care
professionals. Training in most disciplines relevant to CF is
focused on the treatment of acute illnesses (or a series of acute
illnesses), a very different proposition from the long term
management of people with a chronic illness.51 In addition,
physicians receive limited training in communication skills
and in strategies that may enhance the quality of communica-
tion within a consultation. The lack of knowledge about how
adherence can be improved means that most health profes-
sionals receive little specific training about the simple
communication strategies that can promote better adherence
to the health care regimen.52
We have begun to investigate the links between patient
beliefs and perceptions of their disease and its treatment and
their adherence to those treatments. We have conducted a
cross sectional pilot study to assist with the validation of a
new questionnaire measure of beliefs and perceptions about
CF and its treatment and are now using electronic monitoring
technology to collect detailed information from adults with CF
using two different medications over a period of 3 months.53
This will allow us to examine the relationship between
patterns of adherence to those medications and patient beliefs
about their treatments. It is hoped that a better understanding
of treatment adherence in adults with CF will lead to
improvements in treatments, health outcomes, and patient
quality of life.
Few adherence interventions have been tested in patients
with CF—whether children, adolescent, or adult. We believe
that only with greater understanding of the complex issue of
adherence to treatment in people with CF (and other chronic
conditions) will we be able to design and test interventions
that aim to improve and maintain adherence in order to
improve health and wellbeing.
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